Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
ROLL's 24-hour volatility reaches 40.6%: Mainly driven by low liquidity fluctuations, no clear event driver

ROLL's 24-hour volatility reaches 40.6%: Mainly driven by low liquidity fluctuations, no clear event driver

Bitget PulseBitget Pulse2026/04/28 17:34
Show original
By:Bitget Pulse

Volatility Overview

The price of ROLL hit a low of $0.02405 and a high of $0.03381 in the past 24 hours. The current price is $0.03377, with a volatility range of 40.6%. According to CoinGecko data, the 24-hour trading volume is approximately $111,700, with a market capitalization of about $4.53 million. CoinMarketCap shows a 24-hour trading volume of $184,200, with the overall price increasing by 6.3%-6.58%, highs ranging from $0.0316-$0.03169, and lows from $0.0285-$0.02853.

Brief Analysis of Reasons for Unusual Movements

- In the past 24 hours, there were no significant events (such as token unlocking or large whale transfers) detected through official announcements, mainstream news, or on-chain monitoring data.

- Searches on X platform showed no relevant discussions about pump or surge.

Market Views and Outlook

There is limited discussion in the community and on X, with no prevailing market sentiment or analyst forecasts. As a low-cap Base chain project (RollX ecosystem), it is important to monitor the sustainability of trading volume and the overall market environment moving forward, as risks remain high.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Median survival prolonged by 5.7 months! Roche (RHHBY.US) lung cancer new drug wins in head-to-head trial, major catalyst for oncology business

Roche's investigational lung cancer drug divarasib extended patient survival by nearly six months compared to competing therapies in a late-stage clinical trial, promising to further strengthen the Swiss pharmaceutical company's oncology portfolio.

智通财经•2026/10/26 03:11

Global Aging Reshapes Equity and Bond Investment Logic? Pension "Longevity Bill" Accelerates Accumulation, Equities, Bonds, and Private Equity Welcome Massive Long-term Capital

As people live longer and birth rates decline, pension funds are required to allocate their assets for retirement periods that can last decades. Meanwhile, the number of workers contributing to these systems is decreasing.

智通财经•2026/10/26 02:43